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Purpose:  In patients with chronic genotype 1b hepatitis C and a 
high viral load, the viral load was reduced by double filtration 
plasmapheresis (DFPP), followed by combined interferon and ribavirin 
therapy.  The safety and virological effects of this treatment method 
were preliminarily investigated. 
Methods:  In 9 patients with chronic hepatitis C, DFPP was performed 
3 times on days 1, 2, and 4, and the administration of interferon 
and ribavirin was initiated immediately after DFPP on day 1. 
Result:  The HCV RNA was undetectable in all patients after the plasma 
was passed through a plasma fractionator (2nd filter) in the DFPP 
circuit.  After 2 weeks, the HCV RNA tended to decrease in the DFPP 
group more than in the control group(-2.45±1.12 vs. -1.57±0.95, 
p=0.073).  However, this decrease was not attributable to a sustained 
virological response (SVR)(22.2% vs. 18.2%, p=0.822).  Most of the 
adverse events were caused by the interferon and ribavirin 
combination therapy. 
Conclusion:  DFPP can be safely performed concomitantly with 
interferon and ribavirin combination therapy in chronic hepatitis 
C patients.  The combination may contribute to an early virological 
response.  The effect of DFPP on the SVR and its significance remain 
to be clarified.
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 1.  Introduction 
Hepatitis C virus (HCV) infection induces acute hepatitis, and 
approximately 70%–80% of these cases progress to chronic hepatitis.  
The course of the disease is stable in approximately 30% of chronic 
hepatitis cases; however, the remaining 70% of cases progress to 
liver cirrhosis after approximately 30–40 years.  Further, the cases 
that progress to liver cirrhosis develop hepatocellular carcinoma 
at an annual rate of approximately 8% [1]. 
From the viewpoint of viral eradication, interferon therapy 
is the only radical therapy for chronic hepatitis C.  Once complete 
viral elimination is achieved by interferon therapy, liver fibrosis 
improves, and the risk of liver carcinogenesis is reduced [1]. 
In interferon therapy for chronic hepatitis C, administration 
of 3 to 6 × 106 IU interferon alone, 3 times a week for 24 and 48 
weeks, has been reported to produce a sustained virological response 
(SVR) in approximately 6% and 16% of patients, respectively [2].  
Treatment with interferon in combination with ribavirin for 24 and 
48 weeks has been reported to produce an SVR in 21% [3] and 41% [2, 
4, 5] of patients, respectively. 
A combination of pegylated interferon (PEG-IFN)—a recently 
marketed long-acting interferon for once-a-week administration—and 
ribavirin induced an SVR in 47% of patients with chronic genotype 
1b HCV infection and high viral loads in whom previous interferon 
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 therapy failed to produce a response [6, 7]. 
However, even the combination therapy with PEG-IFN and ribavirin 
for 48 weeks, which is currently the most promising therapy, does 
not improve viremia in the other patients for whom there is no 
appropriate therapy for the eradication of HCV viremia other than 
time-course observation and the administration of liver-protective 
drugs.  An NS3 protease inhibitor has been developed as a novel 
antiviral agent, and clinical studies have been performed using this 
agent; however, the clinical application of this drug will take time 
because of the occurrence of certain adverse events [8].  The 
development of an NS5 polymerase inhibitor and an internal ribosome 
entry site (IRES)-targeting agent is in progress [9–11]. 
 The presence or absence of concomitant ribavirin therapy, the 
duration of therapy, the virus genotype, the viral load before 
administration, the grade of liver fibrosis, and the gender and age 
of the patient are all factors that influence the therapeutic effect 
of interferon therapy.  An early virological response (EVR) is defined 
as a decline of more than 2 log10 units in the viral load 8 or 12 weeks 
after the initiation of treatment; it has also been reported to be 
one of the important factors for an SVR [12, 13]. 
There have been several studies in which the HCV level was 
investigated in HCV-positive patients during extracorporeal 
circulation therapies, such as plasmapheresis and hemodialysis.  In 
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 these studies, the HCV RNA level decreased transiently by 
approximately 50%–90% immediately after plasmapheresis or 
hemodialysis; however, it returned to either the pretreatment level 
or to a higher level within approximately 4–6 h [14–17]. 
In double filtration plasmapheresis (DFPP), which is a 
plasmapheresis therapy, the patient’s whole blood is separated into 
plasma and blood cell components by using a plasma separator (1st 
filter).  The separated plasma components are further separated into 
high and low molecular weight components by using a plasma 
fractionator (2nd filter); the high molecular weight components 
including immunoglobulins are removed, and the low molecular weight 
components including albumin are returned to the body.  Although 
this technique using 2 filters is relatively more complicated than 
the normal simple plasma exchange, its advantage is that supplemental 
plasma transfusion is not necessary. 
The diameter of the HCV particle is approximately 55–65 nm [18].  
In theory, these viruses are unable to pass through the 2nd filter 
that has a pore size smaller than the diameter of the viral particle; 
they are therefore eliminated from the plasma. 
In this study, we attempted to reduce the viral loads of patients 
with chronic genotype 1b hepatitis C and a high viral load by using 
DFPP. We focused on HCV RNA levels both before plasmapheresis therapy 
and before interferon and ribavirin combination therapy, and then 
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 investigated the early virological effects and also the safety of 
the treatment. 
 
2.  Experimental/Materials and methods 
2.1.  Patients 
The study involved 9 patients (4 males and 5 females, mean age: 
51.7 ± 11.3 years) with chronic genotype 1b hepatitis C that was 
histologically diagnosed at our department between December 2002 
and July 2004.  In these patients, the HCV RNA level determined by 
reverse transcriptase-polymerase chain reaction (RT-PCR) was not 
less than 100 KIU/ml.  
The inclusion criteria were as follows. (1) Minimum age: 20 
years; maximum age: 70 years. (2) Blood test values before therapy: 
hemoglobin, 12 g/dl or higher; platelet count, 100,000/mm3 or higher; 
white blood cell count, 3,000/mm3 or higher; and neutrophil count, 
1,500/mm3 or higher. 
The exclusion criteria were as follows. (1) Pregnancy or 
possible pregnancy, and lactation; (2) depression; (3) serious 
complications, particularly uncontrollable hypertension and 
impaired function of the bone marrow, kidneys, or the lungs; (4) 
autoimmune diseases or suspicion of the same; (5) diabetes or 
suspicion of the same; (6) allergic predispositions; (7) history 
of hypersensitivity to interferon or nucleic acid analogues; (8) 
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 history of hypersensitivity to biological products such as vaccines; 
(9) suspicion of alcoholic liver injury, autoimmune hepatitis, or 
drug-induced liver injury; (10) multiple infections with hepatitis 
B virus within 48 weeks before the initiation of therapy or suspicion 
of the same; (11) previous hepatic encephalopathy, rupture of the 
esophageal varix, or ascites; (12) complications of hepatic cirrhosis 
or hepatocellular carcinoma on examination within 4 weeks before 
the initiation of therapy or ongoing treatment for the same; and 
(13) treatment with drugs having antiviral actions, immunoregulatory 
actions, or bone marrow-inhibiting actions such as interferon, Ara-A, 
zidopudine, glucocorticoid, interleukin 2, or Shosaikoto within 12 
weeks of the initiation of therapy or administration of injections 
containing glycyrrhizin as the main ingredient, theophylline, 
antipyrine, or warfarin within 4 weeks before therapy. 
 
2.2.  Study design 
This study was conducted in accordance with the Good Clinical 
Practice guidelines, conforming to the Helsinki Declaration.  It 
was approved by the Ethics Committee of Kanazawa University Clinical 
Study Center, and written informed consent was obtained from the 
patients before their participation in the study. 
2.2.1.  Treatment schedule 
 DFPP was performed on day 1 of the therapy to decrease the viral 
 7
 load, and the administration of interferon and ribavirin was 
initiated 1 h after the completion of DFPP.  DFPP was performed 3 
times, on days 1, 2, and 4, and a blood test was performed before 
each treatment to determine the efficacy of the treatment. 
2.2.2.  Double filtration plasmapheresis 
In order to access the blood during DFPP, a Soft-Cell 
double-lumen catheter (GamCath catheter N®; Gambro, Stockholm, 
Sweden) was inserted and indwelled in the right femoral vein for 
5 days.  
For DFPP, a Plasmaflo KM8800 (Kuraray Medical Inc., Tokyo, Japan) 
was used as the dialysis apparatus.  The plasma separator and plasma 
fractionator (1st and 2nd filters, respectively) used were Plasmaflo 
OP-08W® and Cascadeflo EC-50W®, respectively (Asahi Kasei Medical 
Co., Ltd., Tokyo, Japan) (Fig. 1). With regard to the frequency of 
treatment, in a previous study it was observed that the level of 
fibrinogen decreased to less than 100 mg/dl when DFPP was continuously 
performed twice.  Thus, DFPP was discontinued on day 3 to prevent 
fibrinogen-associated complications, such as a tendency to bleed, 
and the applicability of DFPP on day 4 was determined based on 
laboratory test results. 
In order to process 50 ml/kg of blood in a single round of DFPP, 
DFPP was performed for approximately 3 h at a blood flow rate of 
approximately 80 ml/min.  The potent protease inhibitor, Nafamostat 
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 mesilate (Naotamin®; Asahi Kasei Pharma Co., Ltd., Tokyo, Japan), 
was used as an anticoagulant because heparin is considered to 
influence RT-PCR when this procedure is used for HCV RNA measurement.  
For fluid replacement, we used either 50 or 100 ml of 25% albumin 
(Kenketsu Albumin-Wf®; Mitsubishi Pharma Co., Tokyo, Japan) that 
was diluted with 200 ml of saline. 
Blood tests were performed before each DFPP to ensure that the 
plasmapheresis could be performed without the occurrence of any 
adverse events; DFPP was not performed if the platelet count was 
50,000/mm3 or less, or if the fibrinogen level was 100 mg/dl or less.  
The DFPP was resumed after the recovery of these test values was 
confirmed. 
2.2.3.  Interferon therapy 
 For the interferon therapy, interferon (IFN) α-2b (Intron A®; 
Schering-Plough KK, Kenilworth, NJ) and ribavirin (Rebetol®; 
Schering-Plough KK) were concomitantly administered.  IFN α-2b was 
administered intramuscularly 1 h after the completion of DFPP on 
day 1; the oral administration of ribavirin was initiated after the 
completion of DFPP on day 1.  IFN α-2b was administered 6 times a 
week for 2 weeks at a daily dose of 6 × 106 IU, followed by 3 times 
a week for 22 weeks or 3 times a week intermittently for 46 weeks.  
The ribavirin dose was determined based on the body weight measured 
at the time of patient registration.  The dose used was 600 mg and 
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 800 mg for body weights of less than 60 kg and 60 kg or higher, 
respectively.  The daily dose was divided into 2 doses and 
administered orally for 24 weeks. 
2.2.4.  Evaluation 
The HCV RNA was measured during and after therapy by using an 
RT-PCR assay (Amplicor HCV RNA Monitor®; BML, Tokyo, Japan: 
measurement sensitivity, 0.5 KIU or higher); the sample was diluted 
when the HCV RNA level was higher than the upper quantification limit 
(850 KIU/ml).  When the HCV RNA was less than the lower quantification 
limit, a qualitative method was used (Amplicor HCV RNA®, BML; 
measurement sensitivity, 50 IU). 
The HCV RNA was measured after 2, 4, 8, and 12 weeks of therapy, 
either before DFPP or every morning on days 1 to 6.  It was measured 
after 24 and 48 weeks of therapy as well as at 24 weeks after the 
completion of the interferon therapy.  Whenever possible, the HCV 
RNA was also measured immediately after DFPP completion.  The HCV 
RNA in the plasma before and after the 2nd filtration in the DFPP 
circulation was also measured 1 h after the initiation of the DFPP 
and immediately before the completion of the DFPP.  A negative viral 
detection at 24 weeks after the interferon administration was defined 
as an SVR. 
As a control group for a comparison of the decrease in HCV RNA 
during the 2-week therapy period, we used the HCV RNA data of 11 
 10
 patients with chronic genotype 1b hepatitis C and a high viral load 
who underwent IFN and ribavirin combination therapy without DFPP 
at our department during the same period.  
In all patients, a liver biopsy was performed immediately before 
therapy, and fibrosis and inflammation were evaluated based on the 
New Inuyama classification.  The inflammatory activity in the portal 
vein and the periportal area as well as the degrees of intralobular 
inflammation and hepatocyte degeneration were graded from A0 to A3 
(0: none, 1: mild, 2: moderate, and 3: severe) based on the “degree 
of inflammatory activity.”  Fibrosis was also graded from F0 to F4 
(0: none, 1: mild without septa, 2: moderate with few septa, 3: numerous 
septa without cirrhosis, and 4: cirrhosis) [19]. 
For the blood tests, we performed white blood cell, red blood 
cell, platelet, and differential leukocyte (neutrophils, 
eosinophils, basophils, lymphocytes, and monocytes) counts as well 
as the zinc sulfate turbidity test (ZTT).  Further, the percentage 
of hemoglobin, hematocrit, and reticulocytes as well as the levels 
of fibrinogen, total protein, albumin, γ-globulin, and total 
cholesterol were all measured. 
Adverse events were evaluated in accordance with the WHO 
guidelines, and these were classified into mild, moderate, severe, 
and life-threatening events. 
The significance of the differences was analyzed using the 
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 chi-square test, Fisher’s exact test, a t-test, and logistic 
regression analysis. 
 
3.  Results 
3.1.  Patients’ backgrounds 
The patients’ backgrounds are listed in Table 1.  In the DFPP 
group, there were 4 male and 5 female patients with a mean age of 
51.7 ± 11.3 years. The HCV RNA before therapy was at least 100 KIU/ml 
and less than 500 KIU/ml in 3 patients and 500 KIU/ml or higher in 
6 patients, indicating that many of the patients had a high viral 
load.  Three patients had previously undergone IFN therapy, which 
was virologically ineffective.  For the remaining 6 patients, this 
was their first experience of IFN therapy.  With regard to liver 
histology, the fibrosis was graded as F2 or lower in all patients, 
and in all patients there was no evidence of advanced chronic hepatitis.  
Compared with the control group, gender, age, serum HCV RNA, previous 
IFN treatment, liver histology, and blood biochemical data for the 
treatment group were statistically not significantly different.  
 
3.2.  Virological changes after DFPP 
To confirm the elimination of the virus by DFPP, HCV RNA was 
measured before and after the 2nd filtration.  One hour after the 
initiation of DFPP, once the DFPP exchange blood flow had stabilized, 
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 the HCV RNA in the blood after it had passed through the 2nd filter 
was quantitatively undetectable in all 9 patients.  This confirmed 
the elimination of the virus by the 2nd filter (Fig. 2). Further, 
at the completion of DFPP—approximately 3 h after its initiation—the 
HCV RNA was undetectable in all 9 patients (data not shown).  These 
findings confirmed that DFPP is capable of eliminating the HCV 
particles and that the elimination efficiency does not decrease with 
time. 
 
3.3.  Early virological response  
In order to investigate the EVR, the HCV RNA was measured 2 
weeks after the initiation of therapy.  It was quantitatively 
undetectable in 4 of the 9 patients (44.4%). In the control group 
treated with IFN and ribavirin combination therapy without DFPP, 
the HCV RNA was quantitatively undetectable in 2 patients (18.2%).  
The number of patients with undetectable HCV RNA 2 weeks after the 
initiation of therapy was higher in the DFPP group, but the difference 
was not significant (P = 0.201).  
The EVR is defined as a viral load decline of 2 log10 units 
or more from the baseline level at an early stage in the therapy, 
i.e., 2 weeks after the initiation of the therapy in the case of 
this study.  An EVR was achieved in 6 of the 9 patients in the DFPP 
group (66.7%) and in 4 of the 11 patients in the control group (36.4%), 
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 indicating that the HCV RNA tended to decrease earlier during 
concomitant DFPP and interferon therapy; however, the difference 
was not statistically significant (P = 0.178, Fig. 3A). 
The change in HCV viral load also tended to decline more in 
the DFPP group than in the control group (–2.45 ± 1.12 vs. –1.57 
± 0.95; P = 0.073, Fig. 3B).  
 
3.4.  Biochemical response 
The time-course changes in alanine aminotransferase (ALT) are 
shown in Fig. 4.  The ALT level was normalized in 7 of the 9 patients 
(77.8%) by 4 weeks of the therapy. In the control group, it was 
normalized in 7 of the 11 patients (63.6%).  The difference was not 
statistically significant (P = 0.845).  
 
3.5. Sustained virological response  
An SVR was observed in 2 of the 9 patients (22.2%) treated with 
concomitant DFPP and interferon therapy (an intent-to-treat 
approach).  Of these, 1 patient received IFN and ribavirin 
combination therapy for 24 weeks, and the other received IFN and 
ribavirin combination therapy for 24 weeks, followed by additional 
IFN monotherapy for 24 weeks.  These patients were 2 of the 4 patients 
in whom the HCV RNA was quantitatively undetectable after 2 weeks 
of therapy.  Treatment of the other 2 patients was discontinued before 
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 24 weeks due to adverse events (skin eruption, anorexia, and general 
malaise).  In the 6 patients for whom complete treatment was possible, 
the SVR rate was 33.3% (2/6)(a per-protocol approach). 
 In the control group, the SVR rate was 18.2% (2/11) as determined 
using an intent-to-treat approach and 20.0% (2/10) as determined 
using a per-protocol approach. The difference in the SVR rate between 
the 2 groups was not statistically significant (P = 0.822 and P = 
0.551, respectively). 
 The factors associated with the SVR in our patients were analyzed 
using uni- and multivariate analysis. Using univariate analysis, 
the EVR was found to be the only factor associated with SVR (P = 
0.025).  Associations with other factors, such as DFPP, age, sex, 
pre-treatment history, and fibrosis, were not detected in our series 
(P = 0.822, 0.170, 0.822, 0.822, and 0.052, respectively). Using 
multivariate analysis, the association of all of these factors was 
found to be statistically insignificant.  
 In the DFPP group, the only factor showing a relationship with 
the SVR was the viral negativity at 2 weeks (P = 0.014).  
3.6. Safety and adverse events 
In 8 of the patients, DFPP was performed 3 times on days 1, 
2, and 4.  It was not performed on day 4 in 1 patient because this 
patient’s fibrinogen level was lower than 100 mg/dl before DFPP; 
hence, DFPP was performed only twice in this patient. 
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 The changes in laboratory test values as a result of DFPP 
treatment were also investigated.  After DFPP on day 1, the platelet 
count decreased on average by 22.5%.  The decrease persisted until 
the completion of DFPP and then slowly recovered by 2 weeks after 
the initiation of the therapy.  The fibrinogen level decreased by 
30%–50% after DFPP on day 1.  It decreased to its lowest level on 
day 3, slowly recovered after the completion of DFPP, and then returned 
to a level similar to the pre-DFPP level by 2 weeks after the initiation 
of the therapy.  The ZTT values and the γ–globulin and total 
cholesterol levels also showed similar changes.  No change was 
observed in the serum albumin level (Fig. 5). 
The adverse events that occurred during the IFN and DFPP 
combination therapy are listed in Table 2.  Most of these were 
influenza-like symptoms and digestive symptoms that were associated 
with the IFN and ribavirin combination therapy.  The adverse events 
attributable to concomitant DFPP and IFN therapy were mild 
hypotension in 2 patients and mild transient vagal reflex in 1 patient.  
These events occurred during DFPP, and fluid drip injection resulted 
in rapid recovery from these symptoms.  A blood test revealed 
decreases in the hemoglobin as well as in the neutrophil and platelet 
counts; however, these were observed during IFN therapy, suggesting 
that they were unrelated to the DFPP.  The ribavirin dose was reduced 
in 3 patients due to anorexia, anemia, and skin eruption.  The IFN 
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 dose was reduced in 1 patient due to neutropenia.  It was difficult 
to continue the IFN and ribavirin combination therapy in 3 patients 
due to skin eruption, anorexia, and systemic malaise; therefore, 
in these patients the therapy was discontinued. 
 
4.  Discussion 
Currently, the most promising therapy for chronic hepatitis 
C is a 48-week PEG-IFN and ribavirin combination therapy.  Using 
this approach, the SVR is increased in approximately 50% of patients 
[20].  However, in the other half, HCV viremia persists and, although 
ALT is stabilized, hepatitis activity may again increase several 
years later.  Alternatively, chronic hepatitis persists without the 
normalization of ALT and may progress to liver cirrhosis resulting 
in hepatocellular carcinoma.  To prevent these events from occurring, 
it is necessary to develop other novel ideas or novel drugs for therapy.  
With regard to ideas for therapy, long-term IFN therapy extended 
over 48 weeks, the use of intravenously administrable IFN-β, and 
concomitant IFN and high-dose ribavirin therapy with simultaneous 
monitoring of the blood ribavirin concentration, have been 
investigated [21].  With regard to novel drugs, amantadine, IL-12, 
and thymosin-α1 are concomitantly used with IFN therapy or with 
IFN and ribavirin combination therapy [22–24].  With regard to novel 
antiviral agents, the development of an antisense complex targeting 
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 the viral IRES, a serine protease inhibitor targeting NS3 protease, 
and a polymerase inhibitor targeting NS5B have been investigated 
[8–11]. 
Previous reports have described the various factors that affect 
the SVR produced by IFN therapy for chronic hepatitis.  The 
patient-related factors include gender, age, the presence or absence 
of concomitant ribavirin treatment, and the stage of liver fibrosis; 
the viral factors include the viral genotype, HCV RNA level before 
therapy, and the number of mutations in the NS5A interferon 
sensitivity-determining region (ISDR) of genotype 1b [25].  
Recently, an EVR has been recognized as an important factor for 
achieving an SVR using IFN therapy.  An EVR is defined as virus 
elimination at an early stage after the initiation of treatment.  
An EVR in 2 weeks with IFN monotherapy and 12 weeks with IFNα-2b 
and ribavirin combination therapy has been shown to be frequent in 
SVR cases, and the probability of achieving an SVR is high when the 
virus is eliminated from the circulation within these early stages 
[12, 13]. 
In this study, we focused on the HCV RNA level before therapy 
and attempted to reduce the viral load of chronic genotype 1b hepatitis 
C patients, with a high viral load of 100 KIU/ml or higher, by 
performing plasmapheresis therapy, DFPP, before the initiation of 
IFN therapy.  Thus far, this is the first attempt to study the efficacy 
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 of a combination of IFN therapy and plasmapheresis with chronic 
hepatitis C patients.  
In previous studies, Manzin et al. measured the HCV RNA in chronic 
hepatitis C patients with cryoglobulinemia before and after plasma 
exchange; they found that the HCV RNA was reduced by 45.3%–93.3% 
after treatment but returned to its previous level after 4–6 h [14].  
Similarly, Ramratnam et al. observed a decrease in the viral load 
after plasmapheresis in HIV-1- and HCV-positive patients [26].  It 
has also been reported that heparin-induced extracorporeal 
low-density lipoprotein (LDL) precipitation (HELP) apheresis 
decreased the HCV RNA in chronic hepatitis C patients with the 
complication of hypercholesterolemia [16, 17, 27].  The decrease 
in the HCV RNA was transient according to these reports.  By fitting 
a mathematical model to the changes in viral load during IFN therapy, 
HCV production in the liver has been estimated to be 1012 particles 
per day [28].  Although the virus is eliminated from the blood, virus 
production continues in the liver unless it is inhibited by IFN; 
hence, the HCV RNA level may return to the pre-therapy level after 
a few hours.  Therefore we planned to administer IFN immediately 
after the first plasmapheresis.  
We selected DFPP as a plasmapheresis technique because there was 
no necessity to exchange plasma and supplement albumin during the 
apheresis. 
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 Since DFPP is based on the principle of size separation, the 
membrane with a mean pore size of 30 nm that was used as the 2nd 
filter in this study can theoretically be expected to eliminate HCV 
particles with a diameter of 55 to 65 nm.  After the DFPP 2nd filtration, 
the HCV RNA was quantitatively undetectable after performing DFPP 
for 1 h and 3 h; this implies that the filter could eliminate HCV 
particles and that the efficiency did not change with time.  
Other low molecular weight substances, including albumin (MW 
66 kDa) and ribavirin (MW 244 kDa), passed through the 2nd membrane 
and were returned to patient’s blood.  Hence, low molecular weight 
substances were not eliminated by this DFPP system.  
In 7 patients, in whom the serum HCV RNA level could be measured 
before and after DFPP on day 1, the mean rate at which the HCV RNA 
level decreased was 48% (18%–78%); the HCV RNA level did not increase 
again.  This exclusion may have been due to the inhibition of virus 
production by the IFN therapy that was initiated immediately after 
DFPP. 
The EVR after 2 weeks of therapy tended to be higher in the 
DFPP group than in the control group.  The change in viral load after 
2 weeks also tended to decrease more in the DFPP group than in the 
control group.  However, both these differences were statistically 
insignificant.  The virus negativity in the DFPP group after 4 and 
8 weeks was 66.7% and 62.5%, respectively. In the control group, 
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 the HCV RNA levels were not measured periodically and therefore no 
comparison was possible.  However, in a double-blind, controlled 
study in Japan on IFNα-2b and ribavirin combination therapy for 
chronic genotype 1b hepatitis C patients with a high viral load, 
Iino et al. found that the HCV RNA negativity after 4 and 8 weeks 
after the initiation of therapy was 18.8% and 38.2%, respectively.  
This suggested that IFN therapy with a concomitant reduction of the 
viral load using DFPP may induce an early conversion to the HCV 
RNA-negative state.  
In our study, an SVR was observed in 2 of the 9 patients (22.2%) 
in the DFPP group and in 2 of the 11 patients (18.2%) in the control 
group.  These rates are comparable to the result in which an SVR 
was observed in 19.0% of chronic genotype 1b HCV patients after 24 
weeks after the administration of an interferon and ribavirin 
combination therapy [30].  An SVR observed in DFPP group was not 
higher than that in control group although an EVR on 2 weeks in DFPP 
was relatively higher than that in control group. One of the possible 
reasons for this observation is that, in 2 of the 6 patients exhibiting 
an EVR, treatment was discontinued because of the adverse events.  
EVR was demonstrated to be the only factor related to SVR by univariate 
analysis in our study; this may have been because the number of patients 
was insufficient to conduct an accurate analysis of these factors.  
With regard to the safety of the IFN and ribavirin combination 
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 therapy with concomitant DFPP, only mild hypotension and transient 
vagal reflex were observed after the initiation of DFPP, and these 
were rapidly resolved.  There were no other adverse events 
attributable to concomitant DFPP, and the treatment was performed 
safely.  Since DFPP is frequently used in the treatment of severe 
disease conditions, such as malignant rheumatoid arthritis, 
thrombotic thrombopenic purpura, and multiple sclerosis, there may 
be no problems with the application of this procedure to chronic 
hepatitis patients.  During the treatment, a catheter was inserted 
in the right femoral vein for DFPP; however, no infection or accident 
occurred as a consequence of its indwelling.  The other adverse events 
were attributable to the ribavirin and IFN therapy.  
With regard to results of the blood test, the platelet count 
and fibrinogen level slowly decreased from the initiation of therapy 
until the completion of DFPP; however. these gradually recovered 
after the completion of DFPP.  On day 3, the fibrinogen level was 
lower than 100 mg/dl in all but 2 patients.  To ensure the safety 
of the patients, and to prevent complications such as hemorrhage, 
DFPP conducted 3 times on days 1, 2, and 4 during the 1st week of 
therapy may be appropriate for patients with chronic hepatitis C. 
In view of the fact that we found no significant difference 
in the EVR and SVR between the DFPP and control groups, and because 
the number of patients was very small, it was not possible in this 
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 preliminary study to draw conclusions regarding the applicability 
of the DFPP used in conjunction with ribavirin and IFN therapy. It 
could be argued that a simple physical reduction in the viral load, 
induced by concomitant DFPP or other apheresis, is really significant 
for the ribavirin and IFN therapy for chronic hepatitis C patients 
with a high viral load.  Based on our results, it may be possible 
to use DFPP to facilitate early viral elimination.  However, the 
early viral elimination by DFPP was not related to an SVR.  Although 
5 of the 8 patients (62.5%, therapy was discontinued in 1 patient 
after 7 weeks) became virus-negative after 8 weeks, an SVR was observed 
in only 2 patients; thus, the relationship between the early virus 
negativity obtained by DFPP and the SVR remains unclear.  Since the 
early conversion to the virus-negative state is a result of the 
reactivity of the host and virus to ribavirin and IFN, it may be 
possible that a simple physical reduction in the amount of the virus 
is not significant.  However, DFPP eliminates not only the virus 
but also macromolecules including immunoglobulins.  The elimination 
of some humoral factors or complement components by the dialysis 
membrane might be involved.  The state of HCV in the blood, such 
as the immunoglobulin-bound state, the lipoprotein-associated state, 
and the non-bound (free) state, may also be important.  In 2 
preliminary cases, the state of HCV during the treatment was 
investigated using differential flotation centrifugation.  In 
 23
 differential floatation centrifugation, the hyperbaric fraction, 
including the immunoglobulin-bound HCV particles, settles to the 
bottom, whereas the hypobaric fraction, including free-state HCV 
particles, rises to the top.  In the 2 examined cases, the bottom:top 
ratio was reduced after the first DFPP treatment; from 214 to 62 
in case 1 and from 108 to 46 in case 2.  Since a decline in the bottom:top 
ratio indicates an increased amount of free-state HCV particles 
compared to the amount of immunoglobulin-bound HCV particles, these 
results suggest that the occurrence of the free-state HCV increased 
after DFPP.  This increase in the amount of free-state HCV may 
possibly involve an SVR; this supposition is based on a previous 
study that demonstrated that a high proportion of free-state HCV 
was related to an SVR [29]. 
In conclusion, in order to achieve a reduction in the level 
of HCV RNA before IFN therapy and to facilitate an early conversion 
to a virus-negative state, plasmapheresis therapy (DFPP) was 
performed on chronic genotype 1b hepatitis C patients with a high 
viral load.  The therapy was performed without the occurrence of 
severe adverse events, and the results suggested the possibility 
that concomitant DFPP increased the rate of early conversion to a 
virus-negative state.  Since only 9 patients were treated and IFN 
administration was discontinued in 3 patients, the relationship 
between DFPP and an EVR or SVR is unclear.  If an EVR is achieved 
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 by a combination of DFPP and interferon therapy, and this is related 
to an SVR, the combination therapy with DFPP will not only be of 
benefit to chronic hepatitis C patients with a high viral load but 
may also shorten the period of interferon therapy.  Furthermore, 
the cost of interferon therapy will also be reduced, although the 
cost of performing DFPP 3 times will remain high at approximately 
2,500 dollars.  Because our study was limited by the small number 
of patients, further investigations using a study design that 
clarifies the relationship between DFPP and an EVR or SVR are necessary.  
It is also important to further investigate the antiviral effect 
of the PEG-IFN and ribavirin combination therapy with concomitant 
DFPP, and the effects of DFPP other than virus elimination.  In order 
to clarify this relationship, a multi-center clinical trial is being 
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Table 1.  Baseline characteristics of chronic genotype 1b hepatitis 
C patients with a high viral load, treated with a combination of 
DFPP with interferon (IFN) and ribavirin therapy (DFPP group) and 
IFN and ribavirin therapy without DFPP (control group). 
 
Table 2.  Rates of discontinuation of treatment, dose reduction, 






 Figure legends 
 
Fig. 1 Mechanism of double filtration plasmapheresis (DFPP) 
 The blood is separated into plasma and blood corpuscles by the 
plasma separator (1st filter), and then filtered using a plasma 
fractionator (2nd filter) which separates the plasma into low and 
high molecular weight components. 
  
Fig. 2 Change in plasma HCV RNA pre- and post-plasma fractionator 
(2nd filter) 
 In all 9 cases, HCV RNA was not detected in the plasma of the 
post-plasma fractionator filtrate1 h after starting the DFPP. 
 
Fig. 3 Change of HCV RNA load 2 weeks after treatment 
 A.  An EVR is defined as a viral load decline of 2 log10 units 
or more from the baseline level after 2 weeks of treatment. 
 The numbers in each column indicate the ratio of EVR cases/all 
treatment cases. 
 B.  Viral load change after 2 weeks.  Viral load change was 
calculated by the formula; log10 (HCV RNA load after 2 weeks/ HCV 
RNA load at pre-treatment). 
 
Fig. 4 Change in the serum ALT level during treatment  
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  The ALT level was normalized in 8 cases in the 2nd week of 
treatment. 
 
Fig. 5 Changes in the laboratory findings during treatment  
a: Platelet count, b: Fibrinogen, c: ZTT, d: γ-globulin, and e: 
Albumin. 
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Table 1. Baseline characteristics of chronic genotype 1b hepatitis C patients and a high viral load 
treated by concomitant DFPP with interferon (IFN) and ribavirin therapy and control group
DFPP+IFN-R IFN-R P-value
Gender (M/F) 4/5 7/4 0.684
Age 51.7±11.3 50.6±10.6 0.856
Serum HCV-RNA(KIU/mL)
mean (min.-max) 2,162 (224-12,000) 818 (340-1,700) 0.254
100-500/500≦ 3/6 3/8
Previous IFN treatment
Naive/Retreatment 6/3 5/6 0.343
Liver histology
Stage (F0/F1/F2/F3/F4) 1/1/7/0/0 0/5/6/0/0 0.167
Grade (A0/A1/A2/A3) 0/5/3/1 1/7/3/0 0.541
ALT (IU/mL) 88.4±47.7 89.5±34.5 0.957
Hemoglobin (g/dL) 14.0±1.7 14.2±1.2 0.728
Platelet count (×104/μL） 16.9±5.2 15.7±3.4 0.551
Fibrinogen (mg/dL) 231.0±38.9 222.7±92.3 0.804
ZTT (IU) 12.4±4.9 14.2±6.4 0.496
Total protein (mg/dL) 6.9±0.4 6.9±0.4 >0.999
Albumin (g/dL) 4.2±0.3 4.1±0.4 0.373
γ-globulin (g/dL) 1.3±0.2 1.4±0.3 0.492



























Table 2. Rates of discontinuation of treatment, dose reduction, 
and occurrence of adverse events during treatment.





















































IFNα-2b + ribavirinDFPP + IFNα-2b + ribavirin
p=0.073







IFNα-2b + ribavirinDFPP + IFNα-2b + ribavirin












































































































































































































































































































Fig.5 Changes in the laboratory data findings during treatment 
Fig.4 Change of in the serum ALT level during treatment 
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